Harrison.ai develops AI-powered diagnostic products for radiology (Annalise.ai) and pathology (Franklin.ai) to assist clinicians in detecting and categorizing disease. The company aims to scale internationally across the U.S., EMEA and Asia Pacific and to expand AI automation beyond radiology and pathology. Annalise.ai has been monetized since 2022, is operational in more than 1,000 healthcare facilities, supports treatment of over 6 million patients annually, and has regulatory clearance for clinical use in 40 countries including 12 FDA clearances. The firm reports tripling contracted annual recurring revenue for its radiology offering each year for the past three years. Harrison.ai has about 200 employees and now operates in 15 countries, and plans a North American presence in Boston. Its product pipeline includes a Prostate Biopsy offering in development, expected in 2025.

Total raised

$117M

Funding rounds

1

Latest round

Series C

Latest activity

Feb 2025